[1]王立刚 郑延波* 宋雪鹏 刘胜 姜文进 孙博琳 王涛.经导管动脉化疗栓塞联合射频消融治疗原发性肝癌[J].中国微创外科杂志,2015,15(10):883-903.
　Wang Ligang,Zheng Yanbo,Song Xuepeng,et al.Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Primary Hepatocellular Carcinoma[J].Chinese Journal of Minimally Invasive Surgery,2015,15(10):883-903.
点击复制

经导管动脉化疗栓塞联合射频消融治疗原发性肝癌()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
15
期数:
2015年10期
页码:
883-903
栏目:
临床论著
出版日期:
2015-10-20

文章信息/Info

Title:
Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Primary Hepatocellular Carcinoma
作者:
王立刚 郑延波* 宋雪鹏 刘胜 姜文进 孙博琳 王涛
（烟台毓璜顶医院介入治疗科，烟台264000）
Author(s):
Wang Ligang;  Zheng Yanbo;  Song Xuepeng;  et al.
Department of Interventional Therapy, Yantai Yuhuangding Hospital, Yantai 264000, China
关键词:
肝细胞肝癌; 化疗栓塞; 射频消融
Keywords:
Hepatocellular carcinoma; Chemoembolization; Radiofrequency ablation
分类号:
R735.7
文献标志码:
A
摘要:
目的探讨经导管动脉化疗栓塞(transcatheter arterial chemoembolization，TACE)联合CT引导下水循环冷却式射频消融（radiofrequency ablation，RFA）治疗原发性肝癌的临床疗效。方法2011年10月~2014年8月对32例原发性肝癌41个病灶（直径<3.0 cm病灶7个，3.0～4.0 cm 6个，>4.0～5.0 cm 9个，>5.0 cm 19个）采用TACE联合CT导向下水循环冷却式射频消融治疗，联合治疗后第1、3个月行螺旋CT双期增强扫描评价疗效。结果肿瘤影像学评价，完全缓解（complete remission, CR）11个，部分缓解（partial remission, PR）24个，稳定（no change, NC）5个，进展（progressive disease，PD）1个。32例随访10～22个月，31例存活，1例术后13个月因上消化道大出血死亡。结论TACE联合CT引导下水循环冷却式RFA是治疗原发性肝癌安全、微创、有效的方法。
Abstract:
ObjectiveTo analyze the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with CT-guided water circulatory-cooling radiofrequency ablation (RFA) in the treatment of primary hepatocellular carcinoma.MethodsA retrospective analysis was undertaken in 32 patients with 41 nodules of primary hepatocellular carcinoma from October 2011 to August 2014. Seven nodules were less than 3.0 cm in diameter, 6 nodules between 3.0-4.0 cm, 9 nodules between 4.0-5.0 cm, and 19 larger than 5.0 cm. All the patients were treated by TACE combined with CT-guided water circulatory-cooling RFA. All the patients underwent follow-up with enhanced CT scanning after 1 and 3 months.ResultsAccording to the results of the CT scanning, there were 11 complete remission (CR), 24 partial remission (PR), 5 no change (NC) and 1 progressive disease (PD) in all of the nodules. Follow-up reviews for 10-22 months in the 32 patients showed 31 survived and 1 patient died of upper gastrointestinal bleeding.ConclusionTACE combined with CT-guided water circulatory-cooling RFA is a safe, minimal invasive and effective method in the treatment of primary hepatocellular carcinomas.

参考文献/References:

[1]Okabe H, Beppu T, Ishiko T, et al. Preoperative portal vein embolization (PVE) for patients with hepatocellular carcinoma can improve resectability and may improve disease-free survival. J Surg Oncol,2011,104(6):641-646.
[2]Sohn W, Choi MS, Cho JY,et al. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors. Gut Liver,2014,8(5):543-551.
[3]Liu HC, Shan EB, Zhou L, et al. Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects.Chin J Cancer Res,2014,26(4):471-477.
[4]Cao JH, Zhou J, Zhang XL, et al. Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci,2014,34(5):692-700.
[5]中华人民共和国卫生部. 原发性肝癌诊疗规范(2011版).临床肿瘤学杂志,2011,16(10)：929-946.
[6]Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst,2000,92(3):205-216.
[7]Jemal A, Bray F, Center MM, et al．Global Cancer Statistics.CA Cancer J Clin,2011, 61(2):69-90.
[8]Ferlay J, Shin HR, Bray F, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer,2010,127(12):2893-2917.
[9]Goldstein HM, Wallace S, Anderson JH, et al.Transcatheter occlusion of abdominal tumors.Radiology,1976,120(3):539-545.
[10]Georgiads CS, Ramsey DE, Solomon S,et al.New nonsurgical therapies in the treatment of hepatocellular carcinoma.Tech Vasc Interv Radio,2001，4(3):193-199.
[11]吴培宏,张福君,赵明,等. 肝动脉栓塞化疗联合CT导向RFA术治疗中晚期肝癌的评价.中华放射学杂志,2003,37(10):901-904．
[12]陈敏山,李锦清,梁惠宏,等. 经皮射频消融与手术切除治疗小肝癌的疗效比较.中华医学杂志,2005,85(2):80-83.
[13]周铁,孔文韬,仇毓东,等.小肝癌射频消融治疗后患者生存及肝内肿瘤复发的有关因素分析.中国微创外科杂志,2010,10(5):387-394.
[14]Sato M, Watanabe Y, Kashu Y, et al. Sequential percutaneous microwave coagulation therapy for liver tumor.Am J Surg,1998,175(4):322-324.
[15]Buscarini L, Buscarini E.Therapy of HCC-radiofrequency ablation. Hepatogastroenterology, 2001,48(37):15-19.
[16]曹玮.化学药物加温灌注肝癌.国外医学·临床放射学分册,2001,24(1):22-25.
[17]Kim JH, Kim PN, Won HJ, et al. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone. AJR Am J Roentgenol,2014,203(5):1127-1131.
[18]王艳滨,陈敏华,严昆,等.原发性肝癌射频治疗后局部免疫功能的变化及其临床意义.中国微创外科杂志,2006,6(10):803-806.
[19]Raoof M, Zhu C, Kaluarachchi WD, et al. Luciferase-based protein denaturation assay for quantification of radiofrequency field-induced targeted hyperthermia:developing an intracellular thermometer. Int J Hyperthermia,2012,28(3):202-209.
[20]Takeda T, Nakamura K, Sato M, et al. The effect of immunotherapy and hyperthermia on patients with advanced or recurrent cancer-analyses by cancer type and recurrence form.Gan To Kagaku Ryoho,2014,41(10):1261-1263.

备注/Memo

备注/Memo:
*通讯作者，E-mail：yanboz@21cn.com
更新日期/Last Update: 2016-02-03